The existence of a testosterone independent pathway for spermatogenesis, through supraphysiological FSH stimulation, provides a rationale for hormone stimulation therapy in both eugonadal and hypergonadotropic hypogonadism patients (Huhtaniemi, 2018; Oduwole et al., 2018a,b). The gene discussed is BRD2; the disease is Hypergonadotropic hypogonadism.